Medicare has knocked back a bid to give female oncology patients access to a test of ovarian reserve that would help decision making on fertility preservation when undergoing gonadotoxic chemotherapy. An application by clinicians for an MBS item for Anti-Mullerian hormone (AMH) testing in premenopausal female cancer patients was rejected by the Medicare Services Advisory ...
Female oncology patients’ fertility testing rejected by Medicare
By Michael Woodhead
4 Dec 2018